OPGEN INC (OPGN)
US68373L4068 - Common Stock
OPGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While OPGN seems to be doing ok healthwise, there are quite some concerns on its profitability. OPGN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
OPGN had negative earnings in the past year.
OPGN had a negative operating cash flow in the past year.
OPGN had negative earnings in each of the past 5 years.
OPGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
OPGN has a worse Return On Assets (-144.32%) than 85.49% of its industry peers.
With a Return On Equity value of -977.80%, OPGN is not doing good in the industry: 82.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -144.32% | ||
| ROE | -977.8% | ||
| ROIC | N/A |
ROA(3y)-85.23%
ROA(5y)-104.91%
ROE(3y)-239.11%
ROE(5y)-282.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 6.75%, OPGN is in the better half of the industry, outperforming 74.23% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for OPGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OPGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPGN has less shares outstanding
OPGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, OPGN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -25.84, we must say that OPGN is in the distress zone and has some risk of bankruptcy.
OPGN has a worse Altman-Z score (-25.84) than 89.59% of its industry peers.
There is no outstanding debt for OPGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.84 |
ROIC/WACCN/A
WACC5.98%
2.3 Liquidity
A Current Ratio of 0.28 indicates that OPGN may have some problems paying its short term obligations.
OPGN has a worse Current ratio (0.28) than 97.44% of its industry peers.
A Quick Ratio of 0.18 indicates that OPGN may have some problems paying its short term obligations.
OPGN's Quick ratio of 0.18 is on the low side compared to the rest of the industry. OPGN is outperformed by 98.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 65.00% over the past year.
Looking at the last year, OPGN shows a decrease in Revenue. The Revenue has decreased by -7.56% in the last year.
OPGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.05% yearly.
EPS 1Y (TTM)65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q92.33%
Revenue 1Y (TTM)-7.56%
Revenue growth 3Y-9.32%
Revenue growth 5Y-4.05%
Revenue growth Q2Q55.34%
3.2 Future
OPGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.74% yearly.
The Revenue is expected to decrease by -4.26% on average over the next years.
EPS Next Y31.64%
EPS Next 2Y40.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.09%
Revenue Next 2Y-4.26%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OPGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OPGN's earnings are expected to grow with 40.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.74%
EPS Next 3YN/A
5. Dividend
5.1 Amount
OPGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OPGEN INC
NASDAQ:OPGN (5/3/2024, 7:10:27 PM)
After market: 0.48 +0.01 (+2.13%)0.47
-0.02 (-3.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.70M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -144.32% | ||
| ROE | -977.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.56%
Revenue growth 3Y-9.32%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y